| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
FLGT Stock Overview
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally.
Fulgent Genetics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$52.72 |
| 52 Week High | US$112.00 |
| 52 Week Low | US$47.34 |
| Beta | 1.47 |
| 1 Month Change | -10.45% |
| 3 Month Change | 0.69% |
| 1 Year Change | -51.97% |
| 3 Year Change | 349.06% |
| 5 Year Change | 790.54% |
| Change since IPO | 474.29% |
Recent News & Updates
Fulgent Genetics: Poised To Survive Its Post-Covid Hangover
Today, we take a deeper look at Fulgent Genetics, which has benefitted greatly from an explosion of Covid-19 testing revenue. The stock has sold off as fears around the coronavirus have ebbed. However, the company has a huge cash hoard to build up the other parts of its product portfolio. An investment analysis follows in the paragraphs below. "I used to advertise my loyalty and I don't believe there is a single person I loved that I didn't eventually betray." - Albert Camus, The Fall Today, we are putting Fulgent Genetics (FLGT) in the spotlight. The company has been a huge beneficiary of the pandemic. Covid-19 testing revenues powered a thirteen-fold increase in overall sales in the company's 4Q2020 earnings report as a good example of the magnitude of the benefit. Subsequently, the stock rocketed up from $10 a share in March 2020 to $160 in January 2021. Seeking Alpha However, as pandemic fears have ebbed considerably lately, the stock has sold off some 45% since late last year and is down nearly two-thirds from its all-time highs. Time to accumulate some shares in this diagnostic testing concern? An analysis follows below. Company Overview: Fulgent Genetics provides numerous tests and testing services and is based just outside of Los Angeles. Its product portfolio includes Covid-19, molecular diagnostic, and genetic testing. As noted above, the majority of revenues are coming from Covid-19 testing, its specialized oncology and other tests are what the company calls its 'core' revenue-generating part of the company. May Company Presentation The stock sells for around $58.00 a share and sports an approximate market capitalization of $1.75 billion. May Company Presentation First Quarter Results: On May 3rd, Fulgent posted first quarter numbers. The company had non-GAAP earnings of $5.12 a share on revenues of $320 million. Both top and bottom line results easily beat expectations. GAAP profits per share were $4.83. Revenue was down from nearly $360 million in the same period a year ago, solely as a result of a decrease from Covid testing. 'Core' revenue was up 59% to $25.1 million. Management raised its full-year guidance to $660 million worth of sales but took down full year non-GAAP income a buck to $6.00 a share. May Company Presentation Shortly after the quarter closed, Fulgent acquired Inform Diagnostics, a national independent pathology laboratory based in Irving, Texas, for $170 million. May Company Presentation Fulgent Genetics also purchased CSI Laboratories in 2021. May Company Presentation This triggered leadership to move up their estimate of 'core' revenue for FY2022 to approximately $175 million from $120 million previously. At its earnings call in early May, the leadership moved up its estimate for core revenue further to $180 million. May Company Presentation Analyst Commentary & Balance Sheet: Despite a decent-sized market cap, Fulgent Genetics gets short shrift from Wall Street. On January 25th, maintained its Buy rating on FLGT but lowered its price target from $141 to $125 a share. In late May, Piper Sandler reissued its Buy rating after meeting with management. Piper's analyst stated that he was: Impressed with the company's core growth, potential in its COVID business, and "optionality" with its $1.1B in cash. The analyst believes Fulgent is setting itself up to add growth via acquisitions, particularly as other labs struggle with cash management."
Fulgent Genetics, Inc.'s (NASDAQ:FLGT) Low P/E No Reason For Excitement
With a price-to-earnings (or "P/E") ratio of 4x Fulgent Genetics, Inc. ( NASDAQ:FLGT ) may be sending very bullish...
Shareholder Returns
| FLGT | US Healthcare | US Market | |
|---|---|---|---|
| 7D | -11.5% | 1.7% | 1.1% |
| 1Y | -52.0% | 13.5% | -13.0% |
Return vs Industry: FLGT underperformed the US Healthcare industry which returned 12.6% over the past year.
Return vs Market: FLGT underperformed the US Market which returned -12.9% over the past year.
Price Volatility
| FLGT volatility | |
|---|---|
| FLGT Average Weekly Movement | 7.0% |
| Healthcare Industry Average Movement | 9.4% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in US Market | 17.1% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: FLGT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: FLGT's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 645 | Ming Hsieh | https://www.fulgentgenetics.com |
Fulgent Genetics, Inc., together with its subsidiaries, provides COVID-19, molecular diagnostic, and genetic testing services to physicians and patients in the United States and internationally. The company offers genetic tests comprising Focus and Comprehensive oncology panels tests; Beacon carrier screening panels test for inherited conditions; solid tumor molecular profiling for somatic cancer testing; rapid whole genome testing for children in NICU and PICU; newborn genetic analysis panel; single front-line test to detect ataxia-related variants and repeat expansions through sequencing; picture genetics, a patient-initiated genetic testing; whole exome and clinical exome panel tests; whole genome, mutation, and repeat expansion testing services, as well as research service tests. It also provides next generation sequencing and reverse transcription polymerase chain reaction-based tests, as well as antigen-based diagnostic tests for the detection of SARS-CoV-2.
Fulgent Genetics, Inc. Fundamentals Summary
| FLGT fundamental statistics | |
|---|---|
| Market Cap | US$1.60b |
| Earnings (TTM) | US$392.38m |
| Revenue (TTM) | US$925.15m |
4.1x
P/E Ratio1.7x
P/S RatioIs FLGT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FLGT income statement (TTM) | |
|---|---|
| Revenue | US$925.15m |
| Cost of Revenue | US$243.39m |
| Gross Profit | US$681.76m |
| Other Expenses | US$289.38m |
| Earnings | US$392.38m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 12.96 |
| Gross Margin | 73.69% |
| Net Profit Margin | 42.41% |
| Debt/Equity Ratio | 1.6% |
How did FLGT perform over the long term?
See historical performance and comparison